A growing body of research suggests that GLP-1 medications best known for weight loss, such as semaglutide, may also blunt cravings for alcohol and other addictive substances. In one recent trial, moderate-to-heavy drinkers taking an oral form of the drug cut the number of drinks consumed on drinking days roughly in half compared with those on placebo, according to UCHealth.
Participants also reported fewer alcohol-related problems and reduced cravings, with some noting decreased marijuana use as well. A separate observational study that followed more than 227,000 patients found that those taking GLP-1 drugs were hospitalized for drinking-related reasons 36% less often than similar patients not on the medication, according to the Brain & Behavior Research Foundation.
Researchers believe the effect traces back to biology rather than coincidence. GLP-1 receptors cluster in brain regions that govern reward, motivation and stress — the same circuitry implicated in addiction — and at therapeutic doses the drugs appear to dampen dopamine signaling in the brain's core reward center, according to findings summarized by ScienceDaily, making alcohol, nicotine and other substances less rewarding to the brain.
The findings have fueled interest in whether drugs developed for diabetes and obesity could become a new tool against addiction, a field that has seen few pharmaceutical breakthroughs in decades. Semaglutide is not currently approved by regulators for treating alcohol use disorder, and doctors who prescribe it for that purpose are doing so off-label, under medical supervision.
Larger, longer randomized trials are still needed before the drugs could be formally repurposed, researchers caution, but the consistency of results across multiple independent studies has raised optimism among addiction specialists watching the space closely.